MARKET

GMAB

GMAB

Genmab
NASDAQ
33.72
+0.07
+0.21%
After Hours: 33.72 0 0.00% 13:10 12/24 EST
OPEN
33.73
PREV CLOSE
33.65
HIGH
33.89
LOW
33.56
VOLUME
381.83K
TURNOVER
--
52 WEEK HIGH
33.89
52 WEEK LOW
17.24
MARKET CAP
20.76B
P/E (TTM)
13.93
1D
5D
1M
3M
1Y
5Y
1D
Genmab A/S Reports Acquisition of Merus NV Common Shares
Reuters · 1d ago
Lyell Immunopharma pops on recent ASH data, immunotherapy expansion
Seeking Alpha · 1d ago
Weekly Report: what happened at GMAB last week (1215-1219)?
Weekly Report · 2d ago
Genmab A/S reports acquisition of common shares of Merus NV
Reuters · 5d ago
Merus NV Files Initial Beneficial Ownership Statement Naming Genmab A/S as 10% Owner
Reuters · 5d ago
Genmab’s Rina-S: New Study Targets Lung Cancer with Innovative Treatment
TipRanks · 12/17 16:31
Genmab’s Mixed Prospects: Hold Rating Amid Promising Pipeline and Uncertainties
TipRanks · 12/15 17:25
Weekly Report: what happened at GMAB last week (1208-1212)?
Weekly Report · 12/15 09:13
More
About GMAB
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Webull offers Genmab A/S - ADR stock information, including NASDAQ: GMAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GMAB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GMAB stock methods without spending real money on the virtual paper trading platform.